Danaher subsidiaries Beckman Coulter, Cepheid, and Leica Biosystems will be working together with external partners to focus on existing disease areas.

The company reported 5 percent growth in Europe and 3 percent growth in North America, while its revenues in the rest of the world dipped 2 percent.

The development marks a shift up the value chain for labs and could prove a meaningful revenue stream for providers able to ...

China's volume-based procurement policy and US tariffs have forced companies with large business in China to reset their ...

Through clinical trials, partnerships, and economic studies, a crop of test developers is trying to prove the value of their ...

Diagnostics revenue totaled €1.06 billion in Q3 compared to €1.11 billion a year ago, down 4 percent or a fraction of a percent on an adjusted basis.

The 15-minute digital lateral flow immunoassay originally obtained Emergency Use Authorization from the US FDA in 2020.

The funding supports development of an assay to detect and differentiate H5 influenza A from seasonal H1 and H3 subtypes, flu B, and COVID-19.

The funding supports development of an assay to detect and differentiate H5 influenza A from seasonal H1 and H3 subtypes, flu B, and COVID-19.

The company's platform combines microfluidics, cytology, and artificial intelligence-based image analysis for the identification of mild-to-severe dysplasia.

The Uppsala University spinout aims to use its SuperRCA mutation detection technology for applications including molecular residual disease monitoring.

The test, which Santa Maria, California-based Hardy distributes in the US under a license from NG Biotech, is designed to detect CTX-M enzymes.